Sodium phenylbutyrate

Phase 2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Conditions

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Trial Timeline

Jun 30, 2025 → Jul 1, 2027

NCT ID

NCT06773026

About Sodium phenylbutyrate

Sodium phenylbutyrate is a phase 2 stage product being developed by Zevra Therapeutics for Medium-chain Acyl-CoA Dehydrogenase Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06773026. Target conditions include Medium-chain Acyl-CoA Dehydrogenase Deficiency.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07125066	Phase 1	Recruiting	Jul 30, 2025	Dec 1, 2027	Combined D,L-2-hydroxyglutaric Aciduria
NCT06773026	Phase 2	Recruiting	Jun 30, 2025	Jul 1, 2027	Medium-chain Acyl-CoA Dehydrogenase Deficiency

Competing Products

2 competing products in Medium-chain Acyl-CoA Dehydrogenase Deficiency

See all competitors

Product	Company	Stage	Hype Score
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	36
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	33